GlobeStar Therapeutics Corporation

Equities

GSTC

US37960P1049

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 03:51:09 2024-05-02 pm EDT			5-day change	1st Jan Change
0.0008 ^USD	+14.29%		-11.11%	-11.11%

Mar. 12	GlobeStar Therapeutics Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023	CI
2021	Globestar Therapeutics Corporation Reports Earnings Results for the Third Quarter Ended June 30, 2021	CI

GlobeStar Therapeutics Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023

March 12, 2024 at 06:06 am EDT

GlobeStar Therapeutics Corporation reported earnings results for the first quarter ended December 31, 2023. For the first quarter, the company reported net loss was USD 0.163759 million compared to USD 0.165909 million a year ago.

Latest news about GlobeStar Therapeutics Corporation

GlobeStar Therapeutics Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023	Mar. 12	CI
Globestar Therapeutics Corporation Reports Earnings Results for the Third Quarter Ended June 30, 2021	21-08-23	CI

Chart GlobeStar Therapeutics Corporation

Duration

Period

Chart GlobeStar Therapeutics Corporation

More charts

Company Profile

GlobeStar Therapeutics Corporation (GlobeStar Therapeutics) is a clinical-stage pharmaceutical company. The Company is focused on introducing a patented formulation of drugs for the treatment of Multiple Sclerosis and other neurodegenerative diseases. The Company owns the global license from the inventors, who are based in Italy. The Company has acquired a license for a patented method of treating neurodegenerative diseases such as Multiple Sclerosis by administering a synergistically effective amount of the composition to an individual suffering from neurodegeneration and treating neurodegeneration. GlobeStar Therapeutics is initiating discussions with the Food and Drug Administration (FDA) on clinical trial design in preparation for FDA submission and approval pathway.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GLOBESTAR THERAPEUTICS CORPORATION	-11.11%	930K
MODERNA, INC.	+24.94%	48.09B
LONZA GROUP AG	+47.24%	40.62B
IQVIA HOLDINGS INC.	-2.99%	40.43B
CELLTRION, INC.	-6.20%	28.36B
ICON PUBLIC LIMITED COMPANY	+7.40%	24.89B
ALNYLAM PHARMACEUTICALS, INC.	-19.31%	19.01B
MEDPACE HOLDINGS, INC.	+28.62%	12.09B
BIO-TECHNE CORPORATION	-0.87%	11.88B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.99%	11.8B

Other Biotechnology & Medical Research